Entera Bio Ltd. (ENTX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ENTX currently has 46.2M outstanding shares. with significant dilution risk as 114M authorized shares could dilute existing holders by 247.5%. The company has significantly diluted shareholders by 32.68% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 08, 2026 |
S-3 filing: This S-3 filing from Entera Bio Ltd. relates to the offer and resale of up to 19,569,472 ordinary shares by selling shareholders, including shares and shares issuable upon exercise of pre-funded and ordinary share warrants, which were issued in a private placement on April 2, 2026. |
46M | 110M |
| May 08, 2026 |
10-Q filing | 47.8M shares outstanding |
48M | 93M |
| Mar 27, 2026 |
10-K filing | 46.2M shares outstanding |
46M | 95M |
| Aug 08, 2025 |
10-Q filing | 45.1M shares outstanding |
45M | 96M |
| May 30, 2025 |
S-3 filing: Entera Bio Ltd. files an S-3 form to offer ordinary shares, debt securities, warrants, rights and units up to an aggregate initial offering price of $100 million. They are also offering up to 30,000,000 ordinary shares in an at-the-market offering through Leerink Partners. |
43M | 98M |
| May 09, 2025 |
10-Q filing | 43.4M shares outstanding |
43M | 13M |
| Mar 28, 2025 |
10-K filing | 45.4M shares outstanding |
45M | 11M |
| Mar 17, 2025 |
8-K filing: Entera Bio Ltd. issued and sold 3,685,226 ordinary shares to OPKO Health for $8.0 million, at a price of $2.17 per share. ($8.0M proceeds) |
37M | 19M |
| Nov 08, 2024 |
10-Q filing | 37.2M shares outstanding |
37M | 19M |
| Aug 09, 2024 |
10-Q filing | 36.9M shares outstanding |
37M | 19M |
| May 10, 2024 |
10-Q filing | 36.7M shares outstanding |
37M | 19M |
| Mar 08, 2024 |
10-K filing | 35.5M shares outstanding |
35M | 20M |
| Feb 14, 2024 |
S-3/A filing: This prospectus relates to the offer and resale from time to time by the selling shareholders of up to 16,500,894 shares of our ordinary shares. |
29M | 27M |
| Feb 02, 2024 |
S-3 filing: This S-3 filing relates to the offer and resale from time to time by the selling shareholders of up to 16,500,894 shares of ordinary shares. |
29M | 27M |
| Dec 26, 2023 |
8-K filing: Entera Bio Ltd. completed a private placement of 7,916,879 units, each consisting of one ordinary share (or pre-funded warrant) and one ordinary share warrant, for aggregate proceeds of approximately $6.6 million. ($6.6M proceeds) |
29M | 11M |
| Nov 14, 2023 |
10-Q filing | 28.8M shares outstanding |
29M | 11M |
| Aug 11, 2023 |
10-Q filing | 28.8M shares outstanding |
29M | 11M |
| May 05, 2023 |
10-Q filing | 28.8M shares outstanding |
29M | 11M |
| Mar 31, 2023 |
10-K filing | 28.8M shares outstanding |
29M | 11M |
| Nov 10, 2022 |
10-Q filing | 28.8M shares outstanding |
29M | 11M |
| Sep 02, 2022 |
8-K filing: Entera Bio Ltd. entered into a sales agreement with SVB Securities LLC to offer and sell up to 5,000,000 ordinary shares, with a commission rate of 3.0% of the gross sales price. |
29M | 11M |
| Aug 11, 2022 |
10-Q filing | 28.8M shares outstanding |
29M | 16M |
| May 27, 2022 |
S-3 filing: ENTERA BIO LTD may offer from time to time, in one or more offerings, ordinary shares, senior debt securities, subordinated debt securities, warrants, rights and units (collectively, the "securities"). The aggregate initial offering price of the securities that we may offer and sell under this prospectus will not exceed $100.0 million and also offering up to 5,000,000 of ordinary shares through B. Riley Securities. |
29M | 16M |
| May 27, 2022 |
S-3 filing: The selling shareholders may offer and sell up to 3,763,740 of our ordinary shares. |
29M | 16M |
| May 12, 2022 |
10-Q filing | 28.8M shares outstanding |
29M | 6.9M |
| Mar 08, 2022 |
10-K filing | 28.8M shares outstanding |
29M | 6.9M |
| Mar 18, 2021 |
20-F filing | 23.7M shares outstanding |
24M | 12M |
| Jul 13, 2020 |
F-3 filing: This is an F-3 filing for an offering of ordinary shares, senior debt securities, subordinated debt securities, warrants, rights and units with a total proposed amount of $100,000,000. |
18M | 17M |
| Jun 05, 2020 |
F-3 filing: Registration of 9,614,138 ordinary shares offered by selling shareholders. |
18M | 9.6M |
| Mar 26, 2020 |
20-F filing | 18.2M shares outstanding |
18M | 0 |